AGWCA
WST icon

Annis Gardner Whiting Capital Advisors’s West Pharmaceutical WST Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$5.01K – 1259
2026
Q1 		$5.01K Sell
20
-25
-56% -$6.22K ﹤0.01% 959
2025
Q4 		$12.4K Buy
45
+35
+350% +$9.57K ﹤0.01% 731
2025
Q3 		$2.62K Sell
10
-85
-89% -$20.7K ﹤0.01% 852
2025
Q2 		$20.8K Buy
95
+80
+533% +$17.1K 0.01% 565
2025
Q1 		$3.36K Buy
15
+1
+7% +$276 ﹤0.01% 658
2024
Q4 		$4.59K Buy
14
+3
+27% +$944 ﹤0.01% 621
2024
Q3 		$3.3K Sell
11
-88
-89% -$26.9K ﹤0.01% 670
2024
Q2 		$32.6K Hold
99
– – 0.01% 475
2024
Q1 		$39.2K Buy
99
+75
+313% +$27.7K 0.01% 424
2023
Q4 		$8.45K Sell
24
-38
-61% -$13.4K ﹤0.01% 493
2023
Q3 		$23.3K Buy
+62
New +$24K 0.01% 371

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's WST Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of West Pharmaceutical (WST) in Q2 2026, closing a stake of 20 shares — an estimated $5.01K sold.

Annis Gardner Whiting Capital Advisors first reported a position in WST in Q3 2023 and held it in 11 quarters. The position peaked at $39.2K in Q1 2024. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining West Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 20 West Pharmaceutical shares in Q2 2026, an estimated $5.01K.
  • Annis Gardner Whiting Capital Advisors first reported a position in West Pharmaceutical in Q3 2023 and held it in 11 quarters.
  • Annis Gardner Whiting Capital Advisors's West Pharmaceutical position peaked at $39.2K in Q1 2024.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.